To examine the significance of apolipoprotein E (apo E) polymorphism in the hypolipidemic effect of bezafibrate, we evaluated the influence of different apo E phenotypes on serum lipid response to bezafibrate treatment in 58 dyslipidemic patients with WHO phenotypes of Ilb, IV, or isolated hypo-HDL cholesterolemia. Patients were categorized into one of three groups according to apo E phenotypes of E2 (E2/3, n = 5), E3 (E3/3, n = 35), and E4 (E3/ 4 and E4/4, n=18). After 3 months daily administration of 400 mg bezafibrate, serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) levels changed on average in the E3 group [ -8.0% ; p< 0.05 and +1.1% ; not significant (ns), respectively] , the E2 group (-18.3% ; p<0.005 and -26.9%; p<0.05, respectively) and the E4 group (+3.8%; ns and +10.1%; ns, respectively). The changes in TC and LDLC levels in the E4 group was significantly less effective compared with those in the E3 (p < 0.05) and E2 groups (p < 0.01). Bezafibrate induced a reduction in serum triglyceride (TG) levels in the E3 group (-50.1%; p < 0.0001), the E2 group (-46.9% ; p < 0.05) and the E4 group (-44.8% ; p < 0.005). An increase in high-density lipoprotein cholesterol (HDLC) levels was also observed in the E3 group (+ 27.5% ; p< 0.0001), the E2 group (+ 35.0% ; ns) and the E4 group (+ 38.8% ; p< 0.005). However, there was no significant difference in the changes of TG and HDLC levels between the groups. These results suggest an important role of apo E polymorphism in modulating serum lipid response to bezafibrate, and phenotyping of apo E helps predict the therapeutic effect of bezafibrate treatment.
rich lipoprotein particles (10, 11) , the response of serum lipids to bezafibrate could differ between different apo E phenotypes. However, little is known so far about the influence of apo E polymorphism on treatment response to bezafibrate.
In the present study, the author investigated the influence of apo E polymorphism on the response to bezafibrate treatment in dyslipidemic patients. Materials and Methods
Subjects
Fifty-nine dyslipidemic patients with type ll b or IV hyperlipidemia, or isolated hypo-HDL cholesterolemia (HDLC less than 40 mg/dl) (24 men, 35 women ; mean age 56.8+10.7 years) participated in the study. Subjects included 36 patients with non-insulin dependent diabetes mellitus (NIDDM), of whom 14 were treated with diet alone and 22 with oral hypoglycemic drugs. Glycemic control in these patients was stable prior to, and throughout the study. None of the patients were taking lipid-lowering drugs or drugs known to influence serum lipid concentrations, and none of the patients showed evidence of abnormal hepatic or renal functions (serum creatinine more than 1.4 mg/dl or overt proteinuria), or excessive ethanol consumption.
Other concomitant medication was maintained unchanged throughout the study. Subjects were treated as outpatients and given 400 mg of bezafibrate, twice daily.
Samples and analysis
At the onset of the study, blood was obtained from the antecubital vein after overnight fasting and then subsequently at monthly intervals. Serum total cholesterol (TC) and TG concentrations were measured enzymatically and HDLC was measured by direct measurement with a combination of chemical-modified enzymes and sulfated cyclodextrin (Determiner HDL-C, Kyowa Medix Co. Ltd., Tokyo, Japan) (12) using an autoanalyzer (TDA-8OFRNEC, Tohshiba Co. Ltd., Tokyo, Japan). LDLC was calculated using Friedewald's formula (13) for 52 patients whose TG levels were lower than 400 mg/dl. Plasma glucose was measured using the glucose oxidase method. Apo E phenotype was determined by isoelectric focusing of serum samples followed by immunoblotting using antihuman apo E goat serum and then with anti-goat IgG rabbit alkaline phosphatase conjugate (Phenotyping Apo E IEF System, Joko Co. Ltd., Tokyo, Japan) (14). The subjects were divided into the following three groups : the apo E2 group comprised of 5 patients with E2/3 phenotype (because of the opposing effects of a and E 4 alleles, one patient with an E2/4 phenotype was excluded from the present study) ; apo E3 group comprised of 35 patients with E3/3 phenotype ; and apo E4 group comprised of 18 patients with E3/4 and E4/4 phenotypes.
Clinical characteristics of the studied 58 patients according to apo E phenotypes are shown in Table 1 . No statistical difference was found between groups in age, gender ratio, body mass index (BMI) ; the distribution of WHO phenotypes, systolic blood pressure (SBP), diastolic blood pressure (DBP) ; or the prevalence of hypertension, DM, the use of OHA, smoking and alcohol consumption.
Furthermore,there was no difference in fasting plasma glucose (FPG) or glycated hemoglobin (HbA1c). FPG, HbA1c, and BMI in the different apo E groups did not change throughout the study (data not shown).
Effect of apo E polymorphism on serum lipid response to bezafibrate The influence of apo E polymorphism on serum lipid response as well as the percent change expressed as a percentage of the baseline level was evaluated before and 3 months after bezafibrate treatment. Mean lipid levels before and after the treatment with bezafibrate and percent changes in the three apo E groups (n = 58) are shown in Table 2 . No significant difference was found between the apo E groups at baseline and at 3 months after bezafibrate treatment for serum levels of TC, LDLC, TG, and HDLC evaluated. TC and LDLC levels changed on average in the E3 group [-8.0% ; p <0.05 and +1.1% ; not significant (ns), respectively], the E2 group (-18.3%; p< 0.005 and -26.9%; p < 0.05, respectively) and the E4 group (+3.8%; ns and +10.1%; ns, respectively). The change of TC and LDLC levels in the E4 group was significantly less effective compared with those in the E3 (p< 0.05) and E2 groups (p< 0.01). Bezafibrate induced a marked reduction in TG levels in the E3 group (-50.1% ; p<0.0001), the E2 group (-46 . 9%; p < 0.05) and the E4 group (-44.8%; p < 0.005). An increase in HDLC levels was also observed in the E3 group (+27.5%; p < 0.0001), the E2 group (+35.0%; ns) and the E4 group ( + 38.8% ; p<0.005). However, in contrast to the response of TC or LDLC, the effect of bezafibrate treatment on TG and HDLC did not significantly differ among the groups.
Discussion
In the results of this study, the responses of serum TC and LDLC differed in each apo E phenotype group following bezafibrate treatment. The lowest response was found in subjects in the E4 group and the highest response occurred in subjects in the E2 group.
Serum TC and LDLC responses to bezafibrate differed according to WHO phenotypes ; a decrease in type Ila or Ilb patients and an increase in type IV patients (8). The response of plasma cholesterol to dietary therapy is closely correlated with the pre-treatment value of plasma cholesterol (15). However, in the present study, the variance in WHO phenotype distribution or pre-treatment values for serum lipids did not significantly differ among the apo E phenotype groups.
This effect of apo E polymorphism on the response of serum TC and LDLC to bezafibrate treatment may be the result, at least partly, of a more efficient catabolism of the remnants (CM-remnant and IDL) in subjects with the E4 allele, and a less efficient catabolism in subjects with the E2 allele by the hepatic LDL receptor and/or probably the remnant receptor (3, 10). Most of the increased LDL, which is produced by the enhanced catabolism of VLDL with bezafibrate treatment, is cleared from the plasma through LDL receptor-mediated uptake in the liver. The LDL receptor activity in vivo is regulated by the hepatic demand of cholesterol.
A diminished apo E receptormediated uptake of the remnants in subjects with the E2 allele may supply less cholesterol to the liver (3), in addition to blocking endogeneous cholesterol synthesis by bezafibrate treatment (7), thereby enhancing hepatic LDL receptor activity to lower serum LDL levels. Common or enhanced uptake of the remnants in the subjects with the E4 allele will lead to reduced hepatic LDL receptor activity and, eventually, to elevated serum LDL levels.
Carrying of the E4 alleles has been associated with higher levels of TC or LDLC (16-18) and also related to a higher incidence of CAD (19). Although the effects of apo E polymorphism on therapeutic responses to various hypolipidemic agents shows considerable variation, this finding is in agreement with previous reports observing a trend toward a lower response of plasma TC and LDLC levels in E4 carriers with HMG-CoA reductase inhibitors (20, 21) . Because the ability of lipoproteins containing apo E4 phenotype to bind with apo E receptors has been regarded to be the same as the apo E3 phenotype (1 , 2), the underlying mechanism of these observed differences between the E4 and E3 groups in the responses of serum TC and LDLC levels remains to be elucidated. One possibility is the fact that apo E4 has been shown to be associated with the VLDL metabolism because a large amount of apo E4 is present in VLDL, while apo E3 is present in HDL in normal humans (10).
In contrast to the response in serum TC or LDLC levels , no significant relationship was found between the apo E polymorphism and the lowering of serum TG levels or the increase of serum HDLC levels by bezafibrate in these patients.
In addition, investigation of the response to Table 2 . Serum lipid concentrations and percentage of response (% change) according to apo E groups before and after bezafibrate treatment in 58 dyslipidemic patients bezafibrate in two groups also found no significant difference between apo E3/3 carriers (n=35) vs non-apo E3/ 3 carriers (n = 24) (data not shown).
These results suggest that, in these dyslipidemic patients, the reduction in serum TG by bezafibrate treatment is not influenced by a difference in the apo E receptor-mediated uptake of VLDL, CM-remnant, or IDL particles as a result of the apo E polymorphism, and also could suggest that the LPL response that catalizes VLDL to bezafibrate treatment does not depend on the apo E polymorphism, although apo E has been shown to modulate the hydrolysis of TG on TG-rich lipoprotein particles (10, 11). However, since the small number of E2 subjects limited the small sample group in comparison to the other groups, further study is needed to conclude that these mechanisms are responsible for the absence of variability in the effect of bezafibrate on serum TG or HDLC among the different apo E phenotype groups.
In conclusion, apo E polymorphism modulates the plasma lipid response to bezafibrate, and phenotyping of apo E helps predict the outcome of therapy.
Patients with apo E4 respond less efficiently than those with apo E3 or E2 with respect to decreases in TC and LDLC levels, despite the absence of a significant relationship between the apo E phenotypes and the reduction of TG or the increase of HDLC following bezafibrate treatment. 
